Cross Country Healthcare Inc has a consensus price target of $23.2 based on the ratings of 12 analysts. The high is $32 issued by Credit Suisse on February 23, 2023. The low is $16 issued by Truist Securities on February 22, 2024. The 3 most-recent analyst ratings were released by Barrington Research, Benchmark, and Barrington Research on May 6, 2024, May 2, 2024, and February 27, 2024, respectively. With an average price target of $21.33 between Barrington Research, Benchmark, and Barrington Research, there's an implied 29.14% upside for Cross Country Healthcare Inc from these most-recent analyst ratings.
1calculated from analyst ratings
Buy Now | Get Alert | |||||||
---|---|---|---|---|---|---|---|---|
05/06/2024 | Buy Now | 27.12% | Barrington Research | Kevin Steinke | $24 → $21 | Maintains | Outperform | Get Alert |
05/02/2024 | Buy Now | 15.01% | Benchmark | Bill Sutherland | $21 → $19 | Maintains | Buy | Get Alert |
02/27/2024 | Buy Now | 45.28% | Barrington Research | Kevin Steinke | $26 → $24 | Maintains | Outperform | Get Alert |
02/22/2024 | Buy Now | -3.15% | Truist Securities | Tobey Sommer | $22 → $16 | Maintains | Hold | Get Alert |
02/22/2024 | Buy Now | 27.12% | Benchmark | Bill Sutherland | $24 → $21 | Maintains | Buy | Get Alert |
12/06/2023 | Buy Now | — | JMP Securities | Constantine Davides | — | Initiates | → Market Perform | Get Alert |
11/30/2023 | Buy Now | 33.17% | UBS | A.J. Rice | → $22 | Initiates | → Neutral | Get Alert |
11/29/2023 | Buy Now | 57.38% | Barrington Research | Kevin Steinke | $29 → $26 | Maintains | Outperform | Get Alert |
11/03/2023 | Buy Now | 33.17% | Truist Securities | Tobey Sommer | $25 → $22 | Maintains | Hold | Get Alert |
11/03/2023 | Buy Now | 27.12% | Jefferies | Brian Tanquilut | $32 → $21 | Downgrade | Buy → Hold | Get Alert |
10/05/2023 | Buy Now | 93.7% | Jefferies | Brian Tanquilut | $40 → $32 | Maintains | Buy | Get Alert |
08/14/2023 | Buy Now | 75.54% | Barrington Research | Kevin Steinke | $35 → $29 | Maintains | Outperform | Get Alert |
08/08/2023 | Buy Now | 57.38% | Credit Suisse | Jonathan Yong | $27 → $26 | Maintains | Neutral | Get Alert |
06/26/2023 | Buy Now | — | William Blair | Trevor Romeo | — | Initiates | → Outperform | Get Alert |
06/01/2023 | Buy Now | 111.86% | Barrington Research | Kevin Steinke | $42 → $35 | Maintains | Outperform | Get Alert |
05/05/2023 | Buy Now | 63.44% | Credit Suisse | Jonathan Yong | $32 → $27 | Maintains | Neutral | Get Alert |
05/02/2023 | Buy Now | 51.33% | Truist Securities | Tobey Sommer | $38 → $25 | Maintains | Hold | Get Alert |
03/10/2023 | Buy Now | 81.6% | Loop Capital | Joseph France | → $30 | Initiates | → Buy | Get Alert |
02/23/2023 | Buy Now | 142.13% | Benchmark | Bill Sutherland | $45 → $40 | Maintains | Buy | Get Alert |
02/23/2023 | Buy Now | 93.7% | Credit Suisse | Jonathan Yon | $31 → $32 | Maintains | Neutral | Get Alert |
11/07/2022 | Buy Now | 172.4% | Barrington Research | Kevin Steinke | $41 → $45 | Maintains | Outperform | Get Alert |
10/05/2022 | Buy Now | 117.92% | Truist Securities | Tobey Sommer | → $36 | Downgrade | Buy → Hold | Get Alert |
09/15/2022 | Buy Now | 154.24% | Benchmark | Bill Sutherland | $37 → $42 | Maintains | Buy | Get Alert |
06/13/2022 | Buy Now | 123.97% | Benchmark | Bill Sutherland | $42 → $37 | Maintains | Buy | Get Alert |
06/09/2022 | Buy Now | 57.38% | Credit Suisse | Nick Giovacchini | $28 → $26 | Maintains | Neutral | Get Alert |
02/24/2022 | Buy Now | 154.24% | Benchmark | Bill Sutherland | $33 → $42 | Maintains | Buy | Get Alert |
01/27/2022 | Buy Now | 63.44% | Jefferies | Brian Tanquilut | $18 → $27 | Upgrade | Hold → Buy | Get Alert |
08/16/2021 | Buy Now | 15.01% | Credit Suisse | Alexander Khan | — | Maintains | Neutral | Get Alert |
08/05/2021 | Buy Now | 33.17% | Benchmark | Bill Sutherland | — | Upgrade | Hold → Buy | Get Alert |
The latest price target for Cross Country Healthcare (NASDAQ:CCRN) was reported by Barrington Research on May 6, 2024. The analyst firm set a price target for $21.00 expecting CCRN to rise to within 12 months (a possible 27.12% upside). 13 analyst firms have reported ratings in the last year.
The latest analyst rating for Cross Country Healthcare (NASDAQ:CCRN) was provided by Barrington Research, and Cross Country Healthcare maintained their outperform rating.
The last upgrade for Cross Country Healthcare Inc happened on January 27, 2022 when Jefferies raised their price target to $27. Jefferies previously had a hold for Cross Country Healthcare Inc.
The last downgrade for Cross Country Healthcare Inc happened on November 3, 2023 when Jefferies changed their price target from $32 to $21 for Cross Country Healthcare Inc.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Cross Country Healthcare, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Cross Country Healthcare was filed on May 6, 2024 so you should expect the next rating to be made available sometime around May 6, 2025.
While ratings are subjective and will change, the latest Cross Country Healthcare (CCRN) rating was a maintained with a price target of $24.00 to $21.00. The current price Cross Country Healthcare (CCRN) is trading at is $16.52, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.